Cuvposa approved for chronic severe drooling associated with neurologic conditions - ONA
Links shared publicly online about this topic.
- 987total visits
Cuvposa approved for chronic severe drooling associated with neurologic conditions - ONA
View full resource at oncologynurseadvisor.com
Tags: Neurology, Cerebral Palsy, Drug, FDA, Shionogi, Cuvposa
Most Recently Shared on July 29, 2010 at 3:22 pm By:
Cuvposa approved for chronic severe drooling associated with neurologic conditions http://goo.gl/fb/M8Co8
CUVPOSA - New Product Releases - MPR
empr.com — “To reduce chronic severe drooling in patients 3--16yrs of age with neurologic conditions associated with problem drooling (eg, cerebral palsy).” View full resource at empr.com
Most Recently Shared on April 22, 2011 at 2:31 pm By:
MPR News: CUVPOSA: Glycopyrrolate 1mg/5mL; soln; cherry-flavored. http://bit.ly/fQABRJ
Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions - MPR
empr.com — “Cuvposa (glycopyrrolate liquid; Shionogi) has been made available for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3--16 years of age.” View full resource at empr.com
Most Recently Shared on April 8, 2011 at 3:50 pm By:
MPR News: Cuvposa Available for Chronic Severe Drooling Associated with Neurologic Conditions: Cuvposa (glycopyr... http://bit.ly/dEBhht
Shionogi launches CUVPOSA for pediatric chronic severe drooling
news-medical.net — “Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.” View full resource at news-medical.net
Most Recently Shared on April 7, 2011 at 2:09 pm By:
Shionogi launches CUVPOSA for pediatric chronic severe drooling: Shionogi Inc., the U.S.-based group company of ... http://bit.ly/gMBd6q
Shionogi Inc. Announces FDA Approval Of CUVPOSA™ For The Treatment Of Chronic Severe Drooling In Pediatric Patients With Neurologic Conditions
medicalnewstoday.com — “Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of CUVPOSA™ (glycopyrrolate), the first liquid treatment for patie” View full resource at medicalnewstoday.com
Most Recently Shared on July 30, 2010 at 11:39 am By:
Shionogi Inc. Announces FDA Approval Of CUVPOSA For The Treatment Of Chronic Severe Drooling In Pediatric Patients... http://mnt.to/f/3GLX
Cuvposa approved for chronic severe drooling associated with neurologic conditions - MPR
empr.com — “The FDA has approved Cuvposa (glycopyrrolate liquid, from Shionogi), an orphan drug, for the treatment of chronic severe drooling associated with neurologic conditions (eg, cerebral palsy) in patients 3"16 years of age.” View full resource at empr.com
Most Recently Shared on July 29, 2010 at 4:02 pm By:
MPR News: Cuvposa approved for chronic severe drooling associated with neurologic conditions: The FDA has approved... http://bit.ly/ar1eRe
Advertisement
